TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23517508
Drug: Nadroparin treatment
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin treatment in older patients
Study: 16931656
Drug: Large-dose propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Large-dose propofol (Group HiP)
Study: 10632646
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg once daily, plus clarithromycin 250 mg and metronidazole 400 mg twice daily
Study: 10632646
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg twice daily, plus clarithromycin 250 mg and metronidazole 400 mg twice daily
Study: 12060043
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg once daily
Study: 10632646
Drug: pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pantoprazole 40 mg twice daily
Study: 2762658
Drug: Indobufen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indobufen (400 mg/die)
Study: 8020032
Drug: Warfarin (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (oral, INR 2.0-3.5)
Study: 25546465
Drug: ASA 81
Normalized name: ASA 81 MG Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 81 mg once-daily
Study: 25546465
Drug: ASA 325
Normalized name: ASA 325 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 325 mg once-daily
Study: 25546465
Drug: ASA 81
Normalized name: ASA 81 MG Oral Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA 81 mg four times daily
Study: 23324310
Drug: MDA measured
Normalized name: BK-MDA
DrugBank: BK-MDA (DB12809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDA measured in septic rats after intraperitoneal injection of MDR Pseudomonas aeruginosa
Study: 18576334
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg twice weekly plus weekly methotrexate (MTX; > or =15 mg)
Study: 18576334
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly plus weekly methotrexate (MTX; > or =15 mg) plus placebo
Study: 16490020
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (Viagra), flexible-dose (25 mg, 50 mg, or 100 mg) for 10 weeks
Study: 11111392
Drug: ranitidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine plus antibiotics
Study: 11111392
Drug: bismuth plus
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth plus antibiotics
Study: 9179631
Drug: Citalopram (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (adjuvant selective serotonin reuptake inhibitor)
Study: 8473405
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of GIP and GLP-1
Study: 8473405
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of GLP-1 (0.15 pmol/kg.min)
Study: 25946576
Drug: Carbetocin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbetocin (single IV dose)
Study: 25946576
Drug: Oxytocin (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (IV infusion)
Study: 25437032
Drug: Standard multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard multivitamin supplement (sMVS) - contains approximately 100% of the recommended daily allowance (RDA) for iron, vitamin B12, and folic acid
Study: 16030050
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 1000 mg bid for 1 year
Study: 10543488
Drug: 300 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 U/kg of heparin
Study: 10543488
Drug: 150 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 U/kg of heparin
Study: 2286595
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg once daily
Study: 9309373
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg twice daily
Study: 2029814
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and rectal thermometers
Study: 35824
Drug: salazosulphapyridine (SASP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: salazosulphapyridine (SASP) 1 g X 3
Study: 35824
Drug: methyl-salazosulphapyridine (methyl-SASP)
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: methyl-salazosulphapyridine (methyl-SASP) 125 mg x 3
Study: 31818831
Drug: SMS intervention
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS intervention targeting adherence to cardiovascular medications
Study: 28866264
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution 100ml/h for 3 days
Study: 28866264
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous fluid
Study: 23958184
Drug: Usual post-treatment
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Usual post-treatment care (control group)
Study: 21377071
Drug: IV lornoxicam
Normalized name: lornoxicam
DrugBank: Lornoxicam (DB06725)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV lornoxicam 16 mg
Study: 19877047
Drug: dnaJP1 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: dnaJP1 (25 mg daily for 6 months)
Study: 19877047
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of dnaJP1 and hydroxychloroquine (HCQ)
Study: 8236004
Drug: Ketorolac 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 0.5% ophthalmic solution, four times a day for seven days
Study: 17587217
Drug: Duloxetine 60-120
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60-120 mg once daily
Study: 10555898
Drug: L-arginine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine supplementation (8 g daily for 28 days)
Study: 8873688
Drug: Bumetanide (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (0.005 to 0.10 mg/kg)
Study: 1994758
Drug: Patient-controlled sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sedation with midazolam (0.5 mg) and fentanyl (25 micrograms) administered via PCA infuser
Study: 1994758
Drug: Sedation administered
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation administered by the anesthesiologist with 0.5‐1.0 mg intravenous midazolam and 25‐50 micrograms intravenous fentanyl
Study: 6659643
Drug: Disopyramide (Di)
DrugBank: Disopyramide (DB00280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disopyramide (Di) 2.0 mg/kg intravenous
Study: 6659643
Drug: Mexiletine (Me)
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mexiletine (Me) 3.0 mg/kg intravenous
Study: 6659643
Drug: Propafenon (Pr)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenon (Pr) 1.5 mg/kg intravenous
Study: 6659643
Drug: Disopyramide (Di)
DrugBank: Disopyramide (DB00280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disopyramide (Di) 4 X 200 mg/day oral
Study: 6659643
Drug: Mexiletine (Me)
DrugBank: Mexiletine (DB00379)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mexiletine (Me) 4 X 200 mg/day oral
Study: 6659643
Drug: Propafenon (Pr)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenon (Pr) 3 X 300 mg/day oral
Study: 31014344
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered steroids (used as rescue medication)
Study: 25425502
Drug: linagliptin 5mg
Normalized name: LINAGLIPTIN 5MG TAB
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin 5mg once daily
Study: 25425502
Drug: glimepiride 1-4mg
Normalized name: glimepiride 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: glimepiride 1-4mg once daily
Study: 20156769
Drug: Co-trimoxazole (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole (960 mg thrice weekly for 18 months)
Study: 16537811
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in CCG 2891
Study: 16537811
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in CCG 2961
Study: 9870976
Drug: Morphine conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine conditioning with expectation cues
Study: 9870976
Drug: Morphine conditioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine conditioning alone
Study: 8876546
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS), 200 micrograms once daily
Study: 8876546
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate aqueous nasal spray (BDP), 168 micrograms twice daily
Study: 6648357
Drug: Metoprolol, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, administered twice daily over a period of 1 week
Study: 6648357
Drug: Propranolol, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, administered for 1 week
Study: 6648357
Drug: Placebo medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medication for 1 week
Study: 31040253
Drug: Adjuvant zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adjuvant zoledronic acid (4 mg) intravenously at 1, 2, 3, 6, 9, and 12 months after surgery
Study: 27488378
Drug: Tobramycin-impregnated bone
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin-impregnated bone cement (1 g/40 g)
Study: 27488378
Drug: Intravenous tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous tobramycin (control group)
Study: 22036088
Drug: Doxorubicin 75
Normalized name: DOXOrubicin 75 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin 75 mg/m² and cisplatin 100 mg/m² (6 cycles)
Study: 22036088
Drug: Grades 3-4
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Grades 3-4 oral mucositis
Study: 17092664
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy for 3 months followed by 3 months of continuous estrogen and progesterone combined therapy
Study: 17092664
Drug: Continuous estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous estrogen and progesterone therapy for 3 months
Study: 17092664
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (estrogen and progesterone)
Study: 16187913
Drug: TSH levels
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TSH levels below 0.3 mU/L
Study: 16187913
Drug: Normal TSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal TSH levels (0.3-3.0 mU/L)
Study: 16187913
Drug: TSH levels
Normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TSH levels above 3 mU/L
Study: 16187913
Drug: TRAb levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAb levels in relapse group (11.1 IU/L ± 0.17)
Study: 16187913
Drug: TRAb cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAb cutoff value of 1.5 IU/L
Study: 16187913
Drug: TRAb cutoff
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRAb cutoff level of 10 IU/L
Study: 7787129
Drug: saline‐polyethylene glycol
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline‐polyethylene glycol solution (SPG)
Study: 2079572
Drug: 3 megaunits
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 megaunits of recombinant interferon alfa‐2b (INTRON A, R Schering‐Plough, Essex Corporation) subcutaneously thrice weekly for 4 months
Study: 28545195
Drug: Self-administered questionnaire
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered questionnaire assessing knowledge and screening compliance
Study: 25714882
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (3 g/daily)
Study: 23949026
Drug: Premotor Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premotor Therapy
Study: 23949026
Drug: Motor Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor Therapy
Study: 21570514
Drug: Lipid-lowering medications
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering medications (LL)
Study: 16934438
Drug: Lactobacillus paracasei
Normalized name: Lactobacillus Paracasei
DrugBank: Lactobacillus paracasei (DB16551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus paracasei A (100 g/day of fermented milk)
Study: 8592284
Drug: Topical butamben
Normalized name: butamben Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical butamben picrate
Study: 40709
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg single dose)
Study: 31657646
Drug: Withdrawal from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal from methylphenidate treatment
Study: 29357480
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant human EPO (5,000 IU) over 4 weeks (n = 12)
Study: 29357480
Drug: High-dose recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose recombinant human EPO (500 IU·kg body wt‐1·day‐1 for three consecutive days) (n = 12)
Study: 22994682
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both drugs (NAC and ascorbic acid)
Study: 20605202
Drug: rosiglitazone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (2 mg) and metformin (500 mg) twice daily
Study: 20605202
Drug: rosiglitazone and
Normalized name: Rosiglitazone and Glimepiride Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone and metformin
Study: 16962381
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with antiretroviral therapy
Study: 16962381
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (no early treatment)
Study: 12866252
Drug: Fluoxetine (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (n = 54)
Study: 8043704
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate treatment
Study: 31288233
Drug: Ustekinumab intravenous
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab intravenous infusion followed by subcutaneous maintenance dose of 90 mg every 8 weeks
Study: 24479722
Drug: Subconjunctival injection
Normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival injection of 20 mg methylprednisolone
Study: 24479722
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid eye drops (dexamethasone 1 mg/ml)
Study: 7662247
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (quinapril or captopril); duration: 6 months
Study: 7662247
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors (quinapril or captopril)
Study: 29288055
Drug: Atorvastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin + Ticagrelor
Study: 27212277
Drug: Acyclovir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (800 mg five times daily for one week)
Study: 23558303
Drug: High fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fluid management (8 mL/[kg · h])
Study: 23558303
Drug: Low fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fluid management (2 mL/[kg · h])
Study: 20854384
Drug: Cinnamon (2g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon (2g daily for 12 weeks)
Study: 19114297
Drug: Buccal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Buccal midazolam (0.2mg/kg)
Study: 19114297
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam (0.3mg/kg)
Study: 16244023
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg dolasetron IV
Study: 10825320
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg dolasetron IV
Study: 16244023
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron IV
Study: 10825320
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg ondansetron IV
Study: 3716654
Drug: Discontinued group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued group therapy
Study: 3716654
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy (completed treatment)
Study: 3716654
Drug: Standard psychoanalytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard psychoanalytic therapy
Study: 3716654
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (discontinued group therapy)
Study: 16382125
Drug: Overall therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall therapy
Study: 30646650
Drug: Nursing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nursing intervention in addition to routine treatment and respiratory function exercise
Study: 30646650
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment and respiratory function exercise
Study: 27698630
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory medication plus instructions on daily home stretching (control group)
Study: 10367222
Drug: Nitroglycerin patch
Normalized name: Nitroglycerin Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patch (10 mg/24 h) administered four hours before tests in the acute phase.
Study: 10367222
Drug: Nitroglycerin patch
Normalized name: Nitroglycerin Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patch (10 mg/24 h) administered continuously for 25 days in the chronic phase.
Study: 10367222
Drug: ECG-dipyridamole test
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ECG-dipyridamole test after chronic therapy (Dip 2).
Study: 7738625
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens based on platinum derivatives
Study: 1799916
Drug: Brodimoprim 200
Normalized name: brodimoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brodimoprim 200 mg once daily for 7-10 days
Study: 1799916
Drug: Amoxicillin 750
Normalized name: amoxicillin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 750 mg thrice daily for 7-10 days
Study: 7471129
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg clotrimazole vaginal tablet daily for seven days (group I)
Study: 7471129
Drug: Two 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 100 mg clotrimazole vaginal tablets daily for three days (group II)
Study: 31789307
Drug: Tri-modality therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-modality therapy
Study: 28630863
Drug: Melatonin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin at a dose of 2×5 mg with atorvastatin or rosuvastatin at a standardized daily dose of 20 mg
Study: 28630863
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with atorvastatin or rosuvastatin at a standardized daily dose of 20 mg
Study: 24142869
Drug: Efavirenz (EFV)
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz (EFV) 200, 400, and 600 mg daily oral dose
Study: 15283929
Drug: Soy germ
Normalized name: soy germ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy germ isoflavones (60 mg per day, capsules)
Study: 11352236
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with step‐down prednisolone, methotrexate, and sulfasalazine
Study: 9315415
Drug: Norplant implants
Normalized name: Norplant 3-oxime
DrugBank: Norelgestromin (DB06713)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norplant implants
Study: 3328343
Drug: Permethrin-treated bed
Normalized name: Permethrin
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Permethrin-treated bed nets (0.5 g/m2)
Study: 12153372
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine (CAM) use
Study: 21062645
Drug: Moderate-intensity treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity treatment (primary care provider counseling plus additional counseling by an auxiliary staff member)
Study: 21062645
Drug: Low-intensity control
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity control treatment (primary care provider counseling only)